CompletedPhase 3NCT00001033
The Treatment of Tuberculosis in HIV-Infected Patients
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Perlman D, M.D
- Intervention
- Ethambutol hydrochloride(drug)
- Enrollment
- 650 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 1997
Study locations (12)
- USC CRS, Los Angeles, California, United States
- Howard University Hosp., Div. of Infectious Diseases, ACTU, Washington D.C., District of Columbia, United States
- Univ. of Miami AIDS CRS, Miami, Florida, United States
- Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States
- Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
- Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
- SUNY - Buffalo, Erie County Medical Ctr, Buffalo, New York, United States
- NY Univ. HIV/AIDS CRS, New York, New York, United States
- Cornell University A2201, New York, New York, United States
- Beth Israel Med. Ctr. (Mt. Sinai), New York, New York, United States
- Univ. of Cincinnati CRS, Cincinnati, Ohio, United States
- Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00001033 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine